New study aims to sharpen genetic testing for lung cancer

NCT ID NCT07613424

Recruiting now Diagnosis Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study enrolls 1000 people with untreated non-small cell lung cancer to compare different genetic tests for MET gene changes. Participants provide tumor samples for testing, and researchers check how well the tests agree. The goal is to improve diagnosis and guide treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose the right genetic test for lung cancer, leading to more personalized treatment decisions.
What could go wrong: This is an observational diagnostic study, not a treatment trial. It may not directly improve outcomes, and results depend on test accuracy in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site
NOT_YET_RECRUITING

Beijing, China
Research Site
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.